Publications
Search our bibliography using the filters on the right-hand side.
Displaying 251 through 300 of 710 publications.
Skip to main content
Herring W, Gould IG, Ruiz L, Dort T, Zhang Y, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in Spain. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S338.
Purser MF, Mladsi DM, Beckman A, Barion F, Forsey J. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy. Adv Ther. 2018 Oct;35(10):1686-96. doi: 10.1007/s12325-018-0775-0.
Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A. Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK. Epidemiol Infect. 2018 Oct;146(14):1797-806. doi: 10.1017/S095026881800198X
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Wu JJ, Armstrong A. Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 24, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10-a):S78.
Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry S, Feldman S, Armstrong A, Wu JJ. Comparative cost per time in response for tildrakizumab and other targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2018 AMCP NEXUS; October 22, 2018. Orlando, FL. [abstract] J Manag Care Pharm. 2018 Oct; 24(10a):S79.
Brogan AJ, Davis AE, Goodwin B. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PLoS One. 2018 Aug 30;13(8):e0203293. doi: 10.1371/journal.pone.0203293
Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018 Aug 9;36(33):5037-45. doi: 10.1016/j.vaccine.2018.07.005
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301
Talbird SE, Fulton J, La EM, Miao Z, Brogan A, Lewis S. Characteristics and costs of optimized background therapy for treatment of heavily treatment-experienced adults with multidrug-resistant HIV-1 in the US: a clinical trial analysis. Poster presented at the 22nd Annual International AIDS Conference; July 24, 2018. Amsterdam, The Netherlands.
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.
Graham J, Earnshaw S, Burslem K, Lim J. Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations in a U.S. health plan. J Manag Care Spec Pharm. 2018 Jun;24(6):544-53. doi: 10.18553/jmcp.2018.24.6.544
Maurer M, Houghton K, Berroa F, Ensina LF, Guillet G, Labrador M, Gimenez-Arnau AM, Marsland A, Rossi O, Velasco M, Chapman-Rothe N. Angioedema with and without wheals in patients with chronic spontaneous urticaria: findings from the worldwide prospective observational aware study. Presented at the EAACI Congress 2018; May 27, 2018. Munich, Germany.
Brogan AJ, Talbird SE, Davis AE, La EM, Miao Z, Lewis S. Long-term health benefit of ibalizumab in the treatment of adults with multidrug-resistant HIV-1 infection. Presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD.
Lucas A, Wilson M, Wasserman M, Jones D, Vyse A, Slack M, Hilton B, Madhava H, Farkouh R. Dynamic transmission modeling of pneumococcal conjugate vaccine and potential dosing reduction in the United Kingdom. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 17, 2018. Melbourne, Australia.
Wilson M, Wasserman M, Earnshaw S, McDade C, Pugh S, Moffatt M, Sings H, Hilton B, Farkouh R. Predicting invasive pneumococcal disease incidence: a forecasting approach. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Wasserman M, Lucas A, Wilson M, Farkouh R, Brogan A, Hilton B, Jones D. Dynamic transmission modeling to address infant pneumococcal conjugate vaccine schedule modifications. Poster presented at the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); April 16, 2018. Melbourne, Australia.
Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.
Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for vaccinating U.S. adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Buck PO, Curran D, Patterson BJ, Varghese L, Van Oorschot D, Carrico J, Hicks K, Lee BY, Yawn BP. Cost-effectiveness of adjuvanted recombinant zoster vaccine (RZV) for vaccinating US adults not previously vaccinated against herpes zoster. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 25, 2018. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S20.
Zuluaga-Sanchez S, Hess LM, Wolowacz SE, D'yachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for patients with soft tissue sarcoma in the United States. Sarcoma. 2018 Mar 26;2018:6703963. doi: 10.1155/2018/6703963
Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and postherpetic neuralgia case avoidance in the United States for people previously vaccinated against HZ. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the American Society Health System Pharmacist (ASHP) Conference.
Patterson B, Buck P, Pawlowski J, Carrico J, Hicks K, Curran D, Van Oorschot D, Lee B, Yawn B. Assessment of the potential herpes zoster and postherpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the American Pharmacists Association (APhA) Annual Meeting; March 17, 2018. Nashville, TN. Previously presented at the IDWeek 2017 Conference.
Schelfhout J, Jiang Y, Miles L, Merchant S, Graham J. Cost effectiveness of letermovir as cytomegalovirus prophylaxis in in allogeneic hematopoietic stem cell transplant recipients. Poster presented at the 2018 BMT Tandem Meetings; February 2018. Salt Lake City, UT. [abstract] Biol Blood Marrow Transplant. 2018 Mar; 24(3 Supplement):S384. doi: 10.1016/j.bbmt.2017.12.473
Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998
Patterson BJ, Buck PO, Carrico J, Hicks K, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Herpes zoster (HZ) revaccination strategies: assessment of the potential HZ and post herpetic neuralgia case avoidance in the US for people previously vaccinated against HZ. Poster presented at the American Society Health System Pharmacist (ASHP) Midyear Clinical Meeting and Exhibition; December 5, 2017. Orlando, FL.
Purser M, Mladsi D, Beckman A, Barion F, Forsey J. Expected budget impact of expanded use of VNS Therapy®. Poster presented at the American Epilepsy Society 71st Annual Meeting; December 2, 2017. Washington, DC.
Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6
Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Graham J, Talbird SE, Monsanto H, Perez Bolde-Villareal C, Daniels V, Pillsbury M, Wolfson LJ. Budget impact of a one-dose varicella vaccination program using outputs of a dynamic transmission model: Mexican national perspective. Poster presented at the 17th Annual Congress of the Sociedad Latinoamericana de Infectología Pediátrica (SLIPE); November 2017. Cancun, Mexico.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Patterson BJ, Buck PO, Carrico J, Hicks KA, Curran D, Van Oorschot D, Pawlowski JE, Lee BY, Yawn BP. Assessment of the potential herpes zoster and post herpetic neuralgia case avoidance with vaccination in the United States. Poster presented at the IDWeek 2017 Conference; October 6, 2017. San Diego, CA.
Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.
Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.
Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.
Ramamohan V, Mladsi D, Ronquest N, Kamat S, Boklage S. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia. Hospital Practice. 2017 Aug;45(3):111-7. doi: 10.1080/21548331.2017.1324227
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Chronic inducible urticaria (CIndU) in Europe, Central America, and South America: findings from visit 1 of the worldwide AWARE Study. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.
Maurer M, Guillet G, Houghton K, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Treatment of patients with chronic urticaria in Europe: findings from visit 1 of the worldwide prospective observational AWARE study. Poster presented at the EAACI Congress 2017; June 19, 2017. Helsinki, Finland.
Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide AWARE study. Poster presented at the EAACI Congress 2017; June 18, 2017. Helsinki, Finland.
Boye ME, Houghton K, Stull DE, Ainsworth C, Price GL. Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease: MONARCH 1. Poster presented at the 2017 ASCO Annual Meeting; June 4, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).
Wasserman M, Rejas J, Mendez C, Wilson M, McDade C, Moffatt M, Farkouh R. Estimating clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) Pneumococcal Conjugate Vaccine in Spain. Presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 24, 2017. Madrid, Spain.
Wasserman M, Wilson M, Breton MC, Peloquin F, McDade C, Farkouh R. Estimating the clinical and economic impact of switching from the 13-valent Pneumococcal Conjugate Vaccine (PCV13) to a lower-valent (PCV10) vaccine in Canada. Poster presented at the 35th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 23, 2017. Madrid, Spain.
Talbird SE, La EM, Poston SA, Hogea CS. A budget-impact analysis of quadrivalent influenza vaccine use in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A73.
Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.
Curran D, Van Oorschot D, Buck PO, Patterson BJ, Lee BY, Yawn BP, Hicks KA, Carrico J. Cost-effectiveness analysis of Shingrix for vaccinating US adults against herpes zoster. Presented at the ACIP Herpes Zoster Working Group; May 2017. Atlanta, GA.
Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.